French compassionate program tests Last-Hope cancer drug in real patients
NCT ID NCT02310477
Summary
This study followed 704 French patients with advanced colorectal cancer who received regorafenib through a compassionate access program. Researchers wanted to understand how well the drug worked and what side effects occurred in real-world clinical practice, outside of strict clinical trial conditions. The study collected information on survival time, treatment duration, and side effects to help doctors better use this medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Oscar Lambret
Lille, 59020, France
Conditions
Explore the condition pages connected to this study.